Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort

Figures & data

Table 1 Age and gender distribution at the second visit, time period in days

Gender	n	Average age, years	Average days
Male	6	30.33±4.78	64.27±5.22
Female	15	32.33±5.37	63.50±2.87
Total	21	31.76±5.29	64.05±4.69

Note: Data are presented as mean ± standard deviation.

Table 2 Total and item average baseline and final CLDEQ-8 scores and P value

CLDEQ8 items	Initial average	Final average	P-value
1a	2.19±0.39	1.86±0.35	0.002
1b	1.62±0.58	1.48±0.50	0.041
2a	2.38±0.65	1.86±0.47	0.002
2b	1.67±0.56	1.38±0.49	0.015
3a	1.48±0.50	1.38±0.49	0.081
3b	1.29±0.45	1.19±0.39	0.081
4	1.57±0.66	1.52±0.50	0.358
5	1.10±0.61	0.95±0.65	0.133
Total	13.29±1.35	11.62±0.99	0.000

Notes: Data presented as mean ± SD baseline to final and P value from to baseline. CLDEQ-8 = eight item Contact Lens Dry Eye Questionnaire.

Abbreviation: CLDEQ-8, eight-item Contact Lens Dry Eye Questionnaire.

Figure 1 Baseline and final CLDEQ-8 item score.

Notes: Comparison of the eight item Contact Lens Dry Eye Questionnaire (CLDEQ-8) Baseline (initial) and final item scores after using lifitegrast 5% ophthalmic solution treatment (data are mean ± SD). A lower score means reduced symptoms. Improvements in items 1a, 1b, 2a, 2b were statistically significant (P<0.05).
Abbreviation: CLDEQ-8, eight-item Contact Lens Dry Eye Questionnaire.